Article Text
Statistics from Altmetric.com
The Authors’ reply
Kountouras et al comment on probable benefits from omega-3 supplements on various surrogate endpoints for cardiovascular (CV) disease.1 In one of the most recent research synthesis including 17 double-blind randomised controlled trials (RCTs) and more than 80 000 participants, we showed that low-dose omega-3 supplementation (<2 (of 1 g) capsules/day) had no association with CV outcomes with a strong indication that this is unlikely to change over time.2 Since then, two recently published trials, the Long-Term Outcomes Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia (STRENGTH) and the OMega-3 fatty acids in Elderly patients with Myocardial Infarction (OMEMI), tested the effect of medium or high omega-3 dose on CV end points.3 4
OMEMI was a secondary prevention trial conducted in Norway in 1014 elderly people (70–82 years), 2–8 weeks following myocardial infarction (MI). The median triglyceride (TG) levels at baseline were 111 mg/dL and the vast …
Footnotes
Contributors ECR and GM wrote the draft of the document. EEN critically revised it.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
Provenance and peer review Not commissioned; internally peer reviewed.
Linked Articles
- Correspondence
- Cardiac risk factors and prevention